Full-Time
Quality Assurance Technician
Cresilon
51-200 employees
Plant-based hemostatic gel for bleeding control
Compensation Overview
$25/hr
Brooklyn, NY, USA
In Person
Bachelor's
 Manufacturing Quality & Test (1) |
|---|
Get referred to Cresilon
See people who can refer or advise you
- A high school diploma or equivalent is required.
- Experience in Good Manufacturing Practices (GMP) and Food and Drug Administration-regulated environments is required.
- Ability to become gowning qualified under the employer’s standard operating procedure is required.
- Ability to lift, walk, stand, reach, pull, and push is required.
- Sample and visually inspect final products and raw materials, and perform other testing under the direction of the Quality Assurance Operations Manager.
- Perform line-clearance activities and in-process inspections.
- Monitor routine manufacturing operations for conformance to applicable procedures.
- Transfer materials between the two Brooklyn facilities.
- Operate force testers, torque testers, balances, and other testing equipment.
- Report deviations in products, components, raw materials, and equipment according to relevant procedures.
- Perform document-control activities, including printing logbooks and batch records.
- Transcribe data into digital systems for quality-metrics tracking.
- Review batch records and support routine batch disposition.
- A 2- or 4-year degree in Engineering, Science, or Technology/Biotechnology is preferred.
- Experience with ISO 13485:2016 is preferred.
- One year of experience in a regulated industry is highly desirable.
Cresilon makes medical devices that stop bleeding with a plant-based adhesive gel. Its main product, VETIGEL, is a fast-acting gel designed to control bleeding in veterinary patients, and Cresilon serves human trauma and surgical markets as well. The gel is applied to a wound and works to seal and promote clotting within seconds without needing manual pressure. Cresilon differentiates itself by offering a gel-based hemostat and by being among the first to target veterinary applications with a rapid, easy-to-use solution, along with direct sales and partnerships (for example, the VerticalVet Preferred Partnership) to reach clinics and hospitals. The company’s goal is to broaden the gel technology’s uses to improve wound care and save lives across veterinary, human trauma, and surgical settings.
Company Size
51-200
Company Stage
Early VC
Total Funding
$116.5M
Headquarters
New York City, New York
Founded
2010
Get referred to Cresilon
See people who can refer or advise you
Simplify's Take
What believers are saying
- Vizient awarded TRAUMAGEL an Innovative Technology contract on March 2, 2026.
- Cresilon reported July 7, 2026 study data showing durable hemorrhage control.
- Fast Company ranked Cresilon among 2026's World's 50 Most Innovative Companies.
What critics are saying
- Zomedica controls U.S. VETIGEL distribution, compressing Cresilon's veterinary pricing power.
- TRAUMAGEL 2.0's December 2025 clearance raises regulatory-change risk and validation costs.
- Any TRAUMAGEL recall or adverse-event cluster would damage the whole hydrogel platform.
What makes Cresilon unique
- TRAUMAGEL won FDA clearance in August 2024 and 510(k) status.
- Cresilon's plant-based hydrogel stops bleeding without manual pressure, unlike traditional gauze workflows.
- VETIGEL reached Canada in June 2025 through McCarthy Vet, extending distribution reach.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Paid Sick Leave
Paid Holidays
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Disability Insurance
Life Insurance
Commuter Benefits
401(k) Company Match
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 2%2 year growth
↑ 1%Cresilon named one of the World's 50 Most Innovative Companies by Fast Company. * 6 hrs ago PR Newswire NEW YORK, March 25, 2026 Ranked No. 1 in the medical devices category and No. 46 on Fast Company's World's 50 Most Innovative Companies list NEW YORK, March 25, 2026 /PRNewswire/ - Cresilon has been named to Fast Company's World's 50 Most Innovative Companies of 2026. The company ranked No. 1 in the medical devices category and No. 46 overall. This marks the second time Cresilon has earned the top spot in its category, after first being recognized in 2024. "Being named one of the World's 50 Most Innovative Companies and ranked No. 1 in medical devices again speaks to the work our team is doing every day," said Joe Landolina, co-founder and CEO of Cresilon. "We started Cresilon with a clear mission to save lives. Today, TRAUMAGEL is in the hands of first responders and trauma care providers across the country and making a real impact. This recognition reflects the progress we've made and the real-world impact our solution is having in trauma care." Since its last recognition, Cresilon has advanced its hemostatic technology and expanded its reach. TRAUMAGEL(R) received FDA clearance in August 2024 and launched nationwide in January 2025. Clinical use cases reported by critical care providers show TRAUMAGEL saved at least one life per day on average in 2025. The product is now used by first responders and hospitals across the U.S. to control bleeding quickly and help prevent death from severe blood loss, which accounts for more than 35% of prehospital deaths. By the end of 2025, TRAUMAGEL was in use across all targeted care settings, including law enforcement, fire, EMS, and hospital trauma teams. The product is also being evaluated by the U.S. military and has been fielded by select units. To support this growth, Cresilon expanded its manufacturing footprint to 55,000 square feet at its state-of-the-art biomanufacturing facility in Brooklyn. The World's Most Innovative Companies is Fast Company's hallmark franchise and one of its most anticipated editorial efforts of the year. This year's list highlights businesses shaping industry and culture through innovation. Alongside the World's 50 Most Innovative Companies, Fast Company also recognized 720 organizations across 59 sectors and regions. To determine honorees, Fast Company's editors and writers review companies driving progress across industries and regions. They evaluate thousands of submissions through a competitive process. The result is a global look at innovation, from early-stage startups to some of the most valuable companies in the world. "Our list of the Most Innovative Companies is about spotlighting organizations that don't just adapt to change. They drive it," said Brendan Vaughan, editor-in-chief of Fast Company. "The companies we honor this year are setting the pace for their industries and showing what sustained innovation can achieve." The full list of Fast Company's Most Innovative Companies honorees is available at fastcompany.com. It will also appear on newsstands beginning March 31, 2026. About Cresilon Cresilon(R) is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices using its proprietary hydrogel technology. The company's plant-based technology stops bleeding in seconds. Its current and future product lines target trauma care, biosurgery, and animal health. Cresilon's mission is to save lives. The company has been recognized by Fast Company as one of the World's 50 Most Innovative Companies and named an EMS World Innovation Awards winner for TRAUMAGEL. For more information, visit www.cresilon.com. SOURCE Cresilon
Cresilon raised $17 million in a late stage venture capital round following growth in both the company's footprint and distribution network in recent months.
A Park Slope-based biotech startup, Cresilon, has raised $17 million in a late-stage venture capital round. This funding follows recent growth in the company's footprint and distribution network. It marks the third significant fundraising effort since Cresilon received FDA approval for its bleeding-stopping gel.
Revolutionary hemostatic gel for veterinary surgeons available in Canada through leading veterinary supply companyNEW YORK, June 16, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for VETIGEL® to be sold directly to veterinary surgeons in Canada through McCarthy Vet, a full-service veterinary marketing, supply and distribution company exclusively serving veterinarians in the Canadian animal health industry.VETIGEL, a revolutionary plant-based hemostatic gel that instantly stops and controls bleeding, is now available for veterinarian surgeons across Canada through McCarthy Vet. The agreement with McCarthy Vet, a family-owned and operated company that has exclusively served the Canadian veterinary community for over 60 years, is Cresilon's first veterinary distribution partnership in Canada."Our partnership with McCarthy Vet will help us provide more veterinary surgeons with an innovative hemostatic gel that significantly improves the standard of care for pets and animals," said VETIGEL National Sales Manager Brittany Boysen. "VETIGEL has been used by thousands of veterinarians around the world and helps veterinary clinics and animal hospitals save time, reduce operating costs, and improve patient outcomes."Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most effective hemostatic agent when treating animals for traumatic wounds and routine and complex surgical procedures, including dental extractions, liver biopsies, tumor and mass removals, cleft palate repairs, and amputations. To date, the plant-based hemostatic gel for veterinary surgeons has been used in more than 60,000 surgical procedures worldwide.As McCarthy Vet expands its portfolio through a new partnership with VETIGEL, the company remains focused on delivering the solutions today's veterinary professionals need most. This collaboration reflects its ongoing promise to bring innovative products to market that offer meaningful clinical value, ease of use, and better outcomes for patients.As a flowable hemostatic gel, VETIGEL offers veterinary surgeons a safe and efficient way to control bleeding across a wide range of surgical procedures and wound geometries
For more information about Cresilon, which was named to Fast Company's annual list of the World's Most Innovative Companies of 2024, ranking No. 1 in the medical devices category, visit www.cresilon.com.